Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 19c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.07), $0.19 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $19.53 million versus the consensus estimate of $18.37 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Sk Hynix Union Is Finalising Wording Of Tentative Wage Deal, And Will Brief Its Members On The Terms This Afternoon- Reuters
• Evolution Petroleum to buy Midland Basin mineral rights for $16M